Life Science Invest Fund increases investment in AcuCort AB

As communicated to the market yesterday, LSIF has decided to further support the ongoing capital round in AcuCort AB by committing to subscribe for an additional approx. SEK 2,28 mio. bringing our total maximum commitment including guarentees in this round to SEK 12,25 mio. We do this because of our strong belief in AcuCort AB which underlines LSIF's strategy to support the companies in our portfolio. The outcome of the financing round will be known toward the end of this week.